Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib Neoadjuvant Treatment in Resectable Stage II-IIIB EGFR-Mutated NSCLC
NCT05987826Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2023
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective Response Rate at 8 weeks. Started Sep 2023; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05987826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05987826.